If someone you love is struggling with opioid use disorder, or if you're trying to find your own way out, you've probably heard about medication-assisted treatment (MAT). You've also probably heard conflicting things: that it saves lives, that it's "just trading one drug for another," that it works, that it's cheating recovery.
Here's what you need to know: medication-assisted treatment for opioid use disorder is one of the most evidence-supported interventions in all of addiction medicine. It reduces overdose deaths, improves treatment retention, and lowers relapse rates more consistently than abstinence-only approaches. Yet it remains one of the most misunderstood and stigmatized treatments available.
This article cuts through the noise. We'll explain what MAT actually is, how each FDA-approved medication works at the neurological level, who each is appropriate for, and what starting treatment actually looks like. We'll be honest about the limitations too, because MAT isn't a cure and not every patient is a candidate for every medication.
What Medication-Assisted Treatment Actually Is (and Isn't)
Medication-assisted treatment combines FDA-approved medications with counseling and behavioral therapies to treat opioid use disorder. The three medications commonly used are methadone, buprenorphine, and naltrexone. Each works differently in the brain, and each has different administration requirements and appropriate patient populations.
MAT isn't "trading one drug for another." That phrase misunderstands how these medications work. Opioid use disorder changes brain chemistry, specifically the reward pathways and opioid receptors that regulate pain, pleasure, and breathing. These medications stabilize those disrupted systems, allowing the brain to heal while the patient builds a life in recovery.
Think of it like this: we don't tell diabetics they're "trading one drug for another" when they take insulin. We don't tell people with depression they're cheating when they take antidepressants. Opioid use disorder is a chronic medical condition, and medications approved by the FDA help sustain recovery and reduce overdose risk.
The evidence is overwhelming. Study after study shows that MAT reduces overdose deaths, keeps people in treatment longer, helps them return to work and family responsibilities, and lowers rates of infectious disease transmission. It works better than abstinence-only treatment for most patients with moderate to severe opioid use disorder.
The Three FDA-Approved Medications for Opioid Use Disorder
Not all MAT medications work the same way. Understanding the differences helps patients and families make informed decisions about which medication might be the right fit.
Buprenorphine (Suboxone): The Partial Agonist
Buprenorphine is a partial opioid agonist, which means it activates opioid receptors in the brain but only partially, creating a "ceiling effect." You can't get high from it at therapeutic doses, and taking more doesn't increase the effect beyond a certain point. This makes it much safer than full agonists.
The most common formulation combines buprenorphine with naloxone (brand name Suboxone) as a film that dissolves under the tongue. The naloxone is there to prevent misuse: if someone tries to inject Suboxone, the naloxone triggers withdrawal. When taken as prescribed under the tongue, only the buprenorphine is absorbed.
Buprenorphine is effective in outpatient settings and can be prescribed by qualified physicians, nurse practitioners, and physician assistants who have completed required training. This makes it more accessible than methadone, which requires daily clinic visits.
Starting buprenorphine requires careful timing. Because it's a partial agonist, it can actually cause withdrawal if taken too soon after using full opioids. This process, called induction, typically requires waiting until the patient is in mild to moderate withdrawal (usually 12-24 hours after short-acting opioids, longer for long-acting ones like methadone).
What does the first week on buprenorphine feel like? Most patients report that cravings diminish significantly within hours of the first dose. Withdrawal symptoms ease. Energy returns gradually. Some people feel a bit "flat" emotionally at first as their brain adjusts. Sleep can be disrupted initially. These side effects usually improve within the first week or two as the dose is stabilized.
Methadone: The Gold Standard for Severe OUD
Methadone is a long-acting full opioid agonist. It fully activates opioid receptors but does so slowly and steadily, without the rapid high and crash cycle that drives addiction. Methadone reduces cravings, blocks the euphoria from other opioids, and decreases withdrawal symptoms.
It's still considered the gold standard for severe, long-standing opioid use disorder, particularly for patients who haven't succeeded with buprenorphine or who have very high tolerance levels.
The catch: methadone for opioid use disorder can only be dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs), and federal regulations require daily observed dosing, at least initially. Patients must come to the clinic every day to receive their dose under supervision. After demonstrating stability, patients may earn take-home doses for weekends or longer periods.
This daily requirement is both a strength and a limitation. It provides structure and medical oversight, which helps many patients. It also creates logistical barriers, particularly for people with jobs, childcare responsibilities, or transportation challenges. But for patients with severe OUD, especially those who've relapsed multiple times, that daily structure and accountability can be lifesaving.
Naltrexone (Vivitrol): The Abstinence-Required Option
Naltrexone works completely differently from buprenorphine and methadone. It's an opioid antagonist, meaning it blocks opioid receptors entirely. If someone takes opioids while on naltrexone, they won't feel any effect. Naltrexone blocks opioid effects and is used alongside therapy or other services.
The extended-release injectable form, Vivitrol, is given as a monthly shot. Because it blocks receptors rather than activating them, naltrexone doesn't cause physical dependence and isn't a controlled substance.
The critical requirement: patients must be fully detoxed from all opioids before starting naltrexone, typically 7-10 days for short-acting opioids and 10-14 days for long-acting ones. Starting naltrexone too soon triggers severe precipitated withdrawal.
Naltrexone works well for motivated patients who've completed detox and want medication support to prevent relapse. It's often used after residential treatment. It's also appropriate for patients in recovery settings where buprenorphine or methadone aren't philosophically accepted, though this reflects program ideology rather than clinical best practice.
The major safety concern: if someone stops naltrexone and relapses, their tolerance has dropped significantly. The dose they used to take could now cause overdose. This makes the period immediately after discontinuing naltrexone particularly dangerous.
How MAT Integrates with Counseling and Behavioral Health Treatment
Medication alone isn't the complete picture. The most effective treatment combines medication with counseling, therapy, and behavioral health support. That's what the "assisted" in medication-assisted treatment means: the medication assists the therapeutic process.
MAT can be integrated into any level of care. Patients can start buprenorphine in outpatient settings while attending individual therapy. Others begin in residential treatment, stabilize on medication, then step down to partial hospitalization (PHP) or intensive outpatient (IOP) while continuing their medication.
The medication stabilizes brain chemistry and reduces cravings, which creates space for the real work of recovery: processing trauma, learning coping skills, rebuilding relationships, addressing co-occurring mental health conditions, and building a life worth protecting.
Without medication, many patients spend all their energy just fighting cravings and withdrawal. With medication, they can actually engage in therapy. Retention rates prove this: patients on MAT stay in treatment longer and complete programs at higher rates than those on abstinence-only approaches.
For treatment providers, integrating MAT requires clinical infrastructure, trained prescribers, and often specific licensing depending on the medication and state regulations. Programs opening new treatment centers or expanding services need to navigate these requirements carefully.
The Stigma Problem: How Anti-MAT Bias Costs Lives
Here's an uncomfortable truth: some treatment programs refuse to accept patients on MAT. Some require patients to taper off buprenorphine or methadone before admission. Some staff members, even in otherwise excellent programs, communicate subtle or overt disapproval of medication.
This stigma kills people.
When patients are forced to choose between medication that's keeping them alive and accessing residential treatment or sober living, they're put in an impossible position. When they're told they're not "really sober" if they're on medication, they internalize shame that undermines their recovery.
The research is unambiguous: for most patients with moderate to severe opioid use disorder, MAT produces better outcomes than abstinence-only treatment. Lower overdose rates. Better retention. Higher rates of employment and family reunification. These aren't opinions, they're findings from decades of clinical trials and population studies.
The bias against MAT often stems from outdated addiction models, misunderstanding of how these medications work, or philosophical commitments to abstinence that aren't grounded in current neuroscience. Sometimes it comes from people in long-term recovery who succeeded without medication and can't imagine a different path working for others.
Whatever the source, treatment programs that refuse to integrate MAT or that stigmatize patients who use it are operating outside the standard of care. Patients and families should know they have the right to ask whether a program supports medication, how they integrate it, and what the staff's actual attitudes are.
What to Expect as a Patient Starting MAT
If you're considering MAT, here's what the process typically looks like:
Assessment: A qualified provider evaluates your opioid use history, current use patterns, previous treatment attempts, medical history, and psychosocial situation. They'll discuss which medication might be most appropriate and answer your questions.
Induction: For buprenorphine, this means timing your first dose carefully to avoid precipitated withdrawal. Your provider will give you specific instructions about when to take your first dose based on when you last used. For methadone, you'll start at the OTP with a low dose that's gradually increased. For naltrexone, you'll need to complete detox first and pass a naloxone challenge test.
Dose stabilization: Over the first days to weeks, your provider adjusts your dose until you reach a level that eliminates cravings and withdrawal without causing sedation or other problematic side effects. This is individualized. Some patients stabilize quickly, others need more time.
Maintenance: Once stable, you continue your medication while engaging in counseling and building your recovery. How long you stay on medication is an individual decision made with your treatment team. Some people stay on medication for months, others for years, some indefinitely. Research shows longer treatment duration generally produces better outcomes.
Monitoring and support: Regular check-ins with your prescriber, periodic drug screens (not as punishment but as clinical monitoring), and ongoing therapy or support groups help you stay on track. If you're in a structured treatment program, medication management integrates with your other services.
For providers considering adding MAT services, understanding Medicaid billing requirements and reimbursement structures is essential to building a sustainable program.
MAT in the Current Treatment Landscape
Access to MAT continues to expand, though significant barriers remain. Federal regulations have relaxed some restrictions, particularly around buprenorphine prescribing. Telehealth has made medication management more accessible for patients in rural areas or with transportation challenges.
At the same time, policy changes at the federal level continue to shape how treatment programs operate and what services are reimbursed. Providers need to stay informed about regulatory changes that affect MAT delivery.
State-level variations also matter. Licensing requirements, scope of practice regulations, and Medicaid coverage differ significantly. A program opening in Texas faces different requirements than one launching in Tennessee or navigating Ohio Medicaid billing.
Frequently Asked Questions About MAT for Opioid Use Disorder
Is medication-assisted treatment just replacing one addiction with another?
No. This is the most common misconception about MAT. Addiction involves compulsive use despite harm, inability to control use, and continued use despite negative consequences. MAT medications, when taken as prescribed, don't produce euphoria or impairment. They stabilize brain chemistry disrupted by opioid use disorder, allowing people to function normally and engage in recovery. It's treatment, not substitution.
How long will I need to stay on MAT medication?
Treatment duration varies by individual. Some people benefit from 6-12 months of medication while they build recovery skills and stability. Others stay on medication for several years or indefinitely, particularly those with severe, long-standing opioid use disorder. Research shows that longer treatment duration generally produces better outcomes. The decision to taper off medication should be made collaboratively with your treatment team when you're stable and ready, not according to an arbitrary timeline.
Can I get MAT if I'm still using opioids?
Yes, in most cases. Buprenorphine induction requires you to be in early withdrawal, but you don't need to be abstinent for weeks beforehand. Methadone programs accept patients who are actively using. Naltrexone requires complete detox first. The goal of MAT is to help you stop using illicit opioids, and medication makes that transition safer and more achievable. Don't wait until you've achieved perfect abstinence to seek help.
Will MAT show up on a drug test?
Standard drug screens don't typically test for buprenorphine or methadone unless specifically requested. If you're on MAT and subject to drug testing for employment or legal reasons, inform the testing entity and provide documentation from your prescriber. Being on prescribed MAT medication is legal and medically appropriate. Naltrexone doesn't show up on standard opioid drug screens because it's not an opioid.
Can I take MAT medication while pregnant?
Yes, and it's strongly recommended. Both methadone and buprenorphine are safe during pregnancy and far safer than continued opioid use or unmanaged withdrawal. Untreated opioid use disorder during pregnancy carries serious risks for both mother and baby. MAT allows for stable prenatal care and better outcomes. Naltrexone is generally not recommended during pregnancy. If you're pregnant or planning to become pregnant, discuss your options with a provider experienced in treating opioid use disorder in pregnancy.
What happens if I relapse while on MAT?
Relapse doesn't mean treatment failure, and it doesn't mean you should stop your medication. If you use opioids while on buprenorphine or methadone, you'll likely feel less effect due to your tolerance and the medication's blocking properties. Be honest with your treatment team. They can adjust your dose, increase support, and help you get back on track. The medication is there to help you through difficult moments. If you're on naltrexone and relapse, the danger is higher because the medication blocks opioid effects, which can lead to taking dangerous amounts. Reach out for help immediately.
Building MAT-Integrated Treatment Programs That Work
For treatment providers reading this, you already know the clinical case for MAT. The challenge is implementation: navigating licensing requirements, training staff, managing the logistics of medication delivery, billing correctly, and shifting program culture to fully embrace medication as part of comprehensive care.
ForwardCare helps behavioral health treatment centers build MAT-integrated programs with the clinical, licensing, and operational infrastructure to deliver evidence-based care. Whether you're adding MAT to an existing program, opening a new facility, or navigating complex state Medicaid requirements, we provide the systems and support that let you focus on patient care.
We've worked with programs across the country to implement sustainable MAT services that improve outcomes and meet regulatory standards. We understand the clinical realities and the business challenges.
If you're ready to integrate MAT into your treatment program or want to talk through what implementation actually looks like, visit ForwardCare or reach out to our team. Let's build treatment programs that give patients access to the full range of evidence-based interventions they deserve.
